Atara Biotherapeutics Inc (NASDAQ:ATRA) price closed lower on Monday, April 15, dropping -4.15% below its previous close.
A look at the daily price movement shows that the last close reads $0.71. The company’s 5Y monthly beta was ticking 0.72. Taking into account the 52-week price action we note that the stock hit a 52-week high of $3.08 and 52-week low of $0.20. The stock added 7.71% on its value in the past month.
Atara Biotherapeutics Inc, which has a market valuation of $81.00 million, is expected to release its quarterly earnings report May 06, 2024 – May 10, 2024.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give ATRA a short term outlook of 50% Sell on average. Looking at the stock’s medium term indicators we note that it is averaging as a 50% Sell, while an average of long term indicators are currently assigning the stock as 100% Sell.
The overview shows that ATRA’s price is at present -3.61% off the SMA20 and -11.21% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 44.10, with weekly volatility standing at 6.70%. The indicator jumps to 9.60% when calculated based on the past 30 days. Atara Biotherapeutics Inc (NASDAQ:ATRA)’s beta value is holding at 0.70, while the average true range (ATR) indicator is currently reading 0.07.
An analysis of the Atara Biotherapeutics Inc (NASDAQ:ATRA) stock in terms of its daily trading volume indicates that the 3-month average is 2.85 million.
Current records show that the company has 119.36M in outstanding shares. The insiders’ percentage holdings are 7.74% of outstanding shares while the percentage share held by institutions stands at 60.74%. But the 32.33% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.
